What Is Tesamorelin? Synthetic GHRH Analog Research Overview
Introduction
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that has drawn sustained interest from the peptide research community. Classified under CAS registry number 218949-48-5, tesamorelin is distinguished from endogenous GHRH by a specific N-terminal modification that confers enhanced stability in laboratory conditions. This overview examines the molecular architecture of tesamorelin, the signaling pathways it has been observed to engage in published in-vitro studies, the history of its characterization in peer-reviewed literature, and the analytical methods used to verify its purity for research applications.
Molecular Structure and Chemical Identity
Tesamorelin is a 44-amino-acid synthetic peptide based on the sequence of human GHRH(1-44). Its defining structural feature is the addition of a trans-3-hexenoic acid group at the N-terminus, covalently linked to the tyrosine residue at position 1. This lipophilic modification distinguishes tesamorelin from the native GHRH(1-44) amide fragment and is a central focus of structure-activity relationship studies in the literature.
| Property | Detail |
|---|---|
| Peptide classification | Synthetic GHRH(1-44) analog |
| Amino acid count | 44 residues |
| N-terminal modification | Trans-3-hexenoic acid group |
| CAS number | 218949-48-5 |
| Molecular formula | C224H367N63O68S |
| Molecular weight | ~5135.9 Da |
| Sequence basis | Human GHRH(1-44)-NH2 |
The full amino acid sequence follows the endogenous GHRH(1-44) framework: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2, with the trans-3-hexenoic acid moiety appended to the alpha-amino group of Tyr1. This modification has been noted in structural analyses to influence the overall lipophilicity profile of the peptide without altering the core GHRH receptor-binding domain.
Mechanism of Action Studied In Vitro
Published in-vitro research has examined tesamorelin's interaction with the growth hormone-releasing hormone receptor (GHRH-R), a G protein-coupled receptor expressed on somatotroph cell lines. The following signaling events have been characterized in controlled laboratory settings:
GHRH Receptor Binding
Radioligand displacement assays conducted on pituitary cell membrane preparations have demonstrated that tesamorelin binds to the GHRH-R with high affinity. The trans-3-hexenoic acid modification does not appear to impair receptor recognition, as the binding domain resides primarily within the first 29 residues of the GHRH sequence. In-vitro binding studies have suggested that the lipophilic N-terminal group may influence the peptide's interaction kinetics with membrane-associated receptors in cell-based assay systems.
Intracellular Signaling Cascades
Upon GHRH-R engagement in cell culture models, tesamorelin has been observed to activate adenylyl cyclase, leading to elevated intracellular cyclic adenosine monophosphate (cAMP) levels. This cAMP accumulation activates protein kinase A (PKA), which in turn phosphorylates downstream transcription factors. In-vitro studies using somatotroph-derived cell lines have documented the subsequent activation of growth hormone (GH) gene transcription as a downstream consequence of this signaling cascade.
GH-IGF-1 Signaling Pathway
In cell culture systems examining downstream effects, the GH produced following GHRH-R activation has been observed to engage the GH receptor (GHR) on hepatocyte cell lines, triggering the JAK2-STAT5 signaling axis. This pathway has been studied extensively in vitro for its role in regulating insulin-like growth factor 1 (IGF-1) gene expression. The GH-IGF-1 axis represents one of the most well-characterized endocrine signaling pathways in cell biology, and tesamorelin's ability to initiate this cascade in controlled laboratory systems has been a central focus of published research.
Stability Considerations in Assay Conditions
The trans-3-hexenoic acid modification has been investigated for its effect on peptide stability under various in-vitro conditions. Researchers have reported that this structural alteration may reduce susceptibility to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) in cell-free protease assays, which is relevant for researchers designing experiments that require extended incubation periods with intact peptide concentrations.
Published Research History
The scientific literature on tesamorelin spans several decades, reflecting its trajectory from initial characterization to its role as a well-studied research compound:
- Early structural work (1980s-1990s): The foundation for tesamorelin research was laid by studies characterizing the native GHRH(1-44) sequence and systematically exploring N-terminal modifications. These early structure-activity relationship (SAR) studies in cell-based assay systems established that lipophilic acyl modifications could alter peptide pharmacokinetics without diminishing receptor affinity.
- Analog development (late 1990s-2000s): Theratechnologies Inc. developed tesamorelin as a specific GHRH analog, and published studies characterized its binding profile, cAMP induction in somatotroph cell lines, and comparative stability against native GHRH fragments in protease degradation assays.
- Expanded in-vitro characterization (2000s-2010s): A growing body of cell culture studies examined tesamorelin's effects on GH secretion kinetics, dose-response relationships in pituitary cell preparations, and its behavior in multi-cell-type co-culture systems designed to model the GH-IGF-1 axis.
- Contemporary research (2010s-present): Recent literature has focused on tesamorelin in the context of broader GHRH-R signaling studies, including investigations into receptor desensitization kinetics, biased agonism at the GHRH-R, and comparative studies with other GHRH analogs in standardized in-vitro assay platforms.
The compound's presence in peer-reviewed journals, including publications in the Journal of Endocrinology, Endocrinology, and Peptides, reflects its established role as a reference compound in GHRH-R signaling research.
Purity Analysis: How Tesamorelin Quality Is Verified
For in-vitro research, peptide purity is a critical variable that directly impacts experimental reproducibility. Impurities such as truncated sequences, deletion peptides, oxidized variants, or residual synthesis reagents can introduce confounding variables into assay results. Rigorous analytical verification is therefore essential for any research-grade peptide supply.
High-Performance Liquid Chromatography (HPLC)
HPLC is the gold-standard method for assessing peptide purity. Reversed-phase HPLC (RP-HPLC) separates peptide species based on hydrophobicity, producing a chromatographic profile where the target peptide appears as a dominant peak. Purity is calculated as the percentage of total peak area attributable to the target compound. For research-grade tesamorelin, a purity threshold of 98% or higher is generally expected; however, suppliers committed to analytical rigor will routinely exceed this baseline.
Mass Spectrometry Confirmation
Liquid chromatography-mass spectrometry (LC-MS) and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry are used alongside HPLC to confirm molecular identity. These techniques verify that the observed molecular weight matches the theoretical mass of tesamorelin, confirming correct sequence assembly and the presence of the trans-3-hexenoic acid modification.
Origin Research Labs Purity Standards
At Origin Research Labs, every batch of tesamorelin undergoes independent third-party analytical testing by Janoshik Analytical, a laboratory recognized across the research peptide industry for rigorous, unbiased testing. Our current tesamorelin inventory has been verified at >99.832% purity via HPLC, with full Certificates of Analysis (COAs) available for review. Each COA includes the complete HPLC chromatogram, mass spectrometry data, and batch identification for traceability.
How to Evaluate Peptide Quality as a Researcher
When sourcing tesamorelin or any research peptide, the following criteria are essential for evaluating supplier quality:
- Third-party COAs: Certificates of Analysis should be generated by an independent analytical laboratory, not the manufacturer or reseller. Look for named testing facilities with verifiable credentials.
- HPLC purity above 98%: For quantitative in-vitro work, peptide purity below 98% introduces an unacceptable margin of impurity-related variability. Suppliers offering purity above 99% demonstrate a higher standard of synthesis and purification.
- Mass spectrometry confirmation: HPLC alone measures chromatographic purity but does not confirm molecular identity. MS data confirming the correct molecular weight is a non-negotiable component of a complete analytical package.
- Batch traceability: Each vial should be traceable to a specific synthesis batch with corresponding analytical records. This allows researchers to correlate experimental results with specific material lots.
- Proper storage and handling documentation: Lyophilized peptides require specific storage conditions (typically -20C, desiccated, protected from light). Suppliers should provide clear handling instructions to preserve peptide integrity through the research workflow.
Summary
Tesamorelin (CAS 218949-48-5) is a 44-amino-acid synthetic GHRH analog defined by its trans-3-hexenoic acid N-terminal modification. Published in-vitro research has characterized its high-affinity binding to the GHRH receptor, activation of the cAMP/PKA signaling cascade, and downstream engagement of the GH-IGF-1 axis in cell culture systems. Decades of peer-reviewed literature support its use as a well-characterized reference compound for GHRH-R signaling studies.
For researchers requiring verified, high-purity tesamorelin for laboratory use, Origin Research Labs provides material tested at >99.832% purity by independent third-party analysis, with full COA documentation available for every batch.